Evaluate efficacy and toxicity outcomes for patients with HCC. Parzen et al published an analysis from the PCG registry of HCC outcomes but it was limited by the median follow up of only 5 months. Plan to ask institutions to update the follow up on their HCC patients and focus especially on outcomes in patients with larger (>5 cm) HCC and those with CP B/C disease given the sparsity of data in the literature on such patients. Will plan to revaluate local control and overall survival. Also will evaluate DICOM RT data with focus on normal liver dose metrics associated with toxicity, especially V0-15 based on several recent publications demonstrating significance.